Adour Superscience Profile
Key Indicators
- Authorised Capital ₹ 1.50 M
as on 20-12-2024
- Paid Up Capital ₹ 1.50 M
as on 20-12-2024
- Company Age 5 Year, 3 Months
- Last Filing with ROC 31 Mar 2023
About Adour Superscience
The Company is engaged in the Chemicals Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2023. It's a company limited by shares with an authorized capital of Rs 1.50 M and a paid-up capital of Rs 1.50 M, as per Ministry of Corporate Affairs (MCA) records.
Shreyash Vishwakarma and Naveen Sharma serve as directors at the Company.
- CIN/LLPIN
U24100MH2019PTC329954
- Company No.
329954
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
29 Aug 2019
- Date of AGM
30 Sep 2023
- Date of Balance Sheet
31 Mar 2023
- Listing Status
Unlisted
- ROC Code
Roc Mumbai
Industry
Company Details
- Location
Mumbai, Maharashtra, India
- Telephone
- Email Address
- Website
-
- Social Media-
What products or services does Adour Superscience Private Limited offer?
Adour Superscience Private Limited offers a wide range of products and services, including Anti Infective Drugs & Medicines, Anti Infective Agent, TB, Tumor & Cancer Drugs, Anti Cancer Medicines, Brain & Nervous System Drugs, Antidepressant & Anti Anxiety Medicines, Antibiotic Tablets, Capsule & Syrup, Common Disease Medicines, Injectable Products, Anti Cancer Injection.
Who are the key members and board of directors at Adour Superscience?
Board Members(2)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Shreyash Vishwakarma  | Director | 29-Aug-2019 | Current |
| Naveen Sharma | Director | 29-Aug-2019 | Current |
Financial Performance of Adour Superscience.
Enhance accessibility to Adour Superscience's financial data by unlocking access to both Standalone and Consolidated balance sheets, Profit & Loss Statements, Ratios, Related Party Transactions, and additional relevant information.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue | |||||||
| Revenue from Operations | |||||||
| Total Assets | |||||||
| Profit or Loss | |||||||
| Net Worth | |||||||
| EBITDA |
What is the Ownership and Shareholding Structure of Adour Superscience?
Unlock access to Adour Superscience's control and ownership data, Corporate Shareholding Patterns, Funding (security allotment) details, Foreign Institutional Investor information, Directors and Key Management Personnel (KMP) Remuneration, Group Structure, Overseas Direct Investment and other pertinent data.
Related Corporates (Common Directorship)
Adour Mediventure Private LimitedActive 5 years 5 monthsShreyash Vishwakarma and Naveen Sharma are mutual person
Charges (Loans)
There are no open charges registered against the company as per our records.
How Many Employees Work at Adour Superscience?
Unlock and access historical data on people associated with Adour Superscience, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Adour Superscience, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Adour Superscience's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
